Metastatic Colorectal Cancers Recruiting Phase 2 Trials for Regorafenib (DB08896)

Also known as: Colorectal cancer metastatic / Metastatic Colorectal Cancer

IndicationStatusPhase
DBCOND0063579 (Metastatic Colorectal Cancers)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04030260Regorafenib and Nivolumab in Combination With Radiotherapy for pMMR/MSS Metastatic Colorectal CancerTreatment
NCT03880877Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated in Patients With Previously Treated Metastatic Colorectal CancerTreatment
NCT02466009Regorafenib in Metastatic Colorectal CancerTreatment
NCT03010722Prospective Translational Study Investigating Molecular Predictors of Resistance and Response to Regorafenib Monotherapy